For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major ...

Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia and is approved and ...

For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major ...

Explore the role of depression drugs targeting the neurokinin-1 receptor and their potential impact on major depressive ...

The P2Y14 receptor, a G protein-coupled receptor activated by extracellular UDP-sugars, has emerged as a significant mediator in immune responses and inflammation. Although originally identified for ...

Combination of AT7687 and cagrilintide demonstrated enhanced weight loss effect in obese, insulin-resistant, pre-diabetic non ...

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) ("Amylyx" or the "Company") today announced the selection of AMX0318, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist, as a development ...

Amylyx Pharmaceuticals has named Dan Monahan as chief commercial officer, positioning an exec who led the U.S. commercialization of Rexulti to oversee the planned launch of a GLP-1 receptor antagonist ...

IDOR-1117-2520 is now in a Phase 2 proof-of-concept trial in psoriasis, with the potential to expand into additional autoimmune conditions where the CCR6-CCL20 pathway plays a pathogenic role.

Dr. Hans Eriksson, Chief Medical Officer, presented clinical findings from the OLIVE Phase 2b trial, which evaluated BH-200 (nelivaptan) in 338 patients with Major Depressive Disorder (MDD), using a ...

For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major depressive disorder. Early studies suggested promise, but enthusiasm faded after ...